Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study

International Journal of Cancer

Volumn 119, Issue 10, 2006, Pages 2398-2401

  Cantwell, Marie M ^a,c   Lacey Jr , James V ^a   Schairer, Catherine ^a   Schatzkin, Arthur ^a   Michaud, Dominique S ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Age at menarche; Bladder cancer; Estrogen; Hormone therapy; Menopause; Parity; Reproductive factors

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; EUROPE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCTION; SEX DIFFERENCE; UNITED STATES;

AGE FACTORS; AGED; BODY MASS INDEX; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENARCHE; MENOPAUSE; MIDDLE AGED; ODDS RATIO; PARITY; PREGNANCY; PROSPECTIVE STUDIES; REPRODUCTIVE HISTORY; RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33749617449     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22175     Document Type: Article

References (32)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER 1975-2001. Surveillance Research Program, Cancer Statistics Branch, National Cancer Institute, DCCPS, Bethesda, MD, 2004.
2. Thorn M, Bergstrom R, Johansson AM, Ramstrom L, Persson I, Malmstrom PU. Trends in urinary bladder cancer incidence in Sweden 1960-93 with special reference to histopathology, time period, birth cohort, and smoking. Cancer Causes Control 1997;8:560-7.
3. Hayne D, Arya M, Quinn MJ, Babb PJ, Beacock CJM, Patel HRH. Current trends in bladder cancer in England and Wales. J Urol 2004; 172:1051-5.
4. Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, Mott LA, Silverman D, Karagas M. Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control 2004;15:759-69.
5. Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC. Gender-and smoking related bladder cancer risks. J Natl Cancer Inst 2001;93:538-45.
6. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, Fraumeni JF, Jr. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990;82:1636-40.
7. Terada S, Suzuki N, Uchide K, Akasofu K, Nishida E. Effect of testosterone on the development of bladder tumors and calculi in female rats. Gynecol Obstet Invest 1992;34:105-10.
8. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972;8: 587-94.
9. IARC Working Group. Hormonal contraception and post menopausal hormonal therapy. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 72. IARC, Lyon, 1999. 1-492.
10. Miller AB, Barclay TH, Choi NM, Grace MG, Wall C, Plante M, Howe GR, Cinader B, Davis FG. A study of cancer, parity and age at first birth. J Chronic Dis 1980;33:595-605.
11. Plesko I, Preston-Martin S, Day NE, Tzonou A, Dimitrova E, Somogyi J. Parity and cancer risk in Slovakia. Int J Cancer 1985;36:529-33.
12. Green A, Beral V, Moser K. Mortality in women in relation to their childbearing history. BMJ 1988;297(6645):391-5.
13. Cantor KP, Lynch CF, Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 1992;3:57-62.
14. Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S. Smoking and other risk factors for bladder cancer in women. Prev Med 2002;35:114-20.
15. McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006;163:236-44.
16. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5: 491-500.
17. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
18. Lacey JV, Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
19. Kato I, Toniolo P, Koenig KL, Kahn A, Schymura M, Zeleniuch-Jacquotte A. Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol 1999;149:372-8.
20. Breslow NE, Day NE. Statistical methods in cancer research. In: Breslow NE, Day NE, eds. The design and analysis of cohort studies, vol. 2. Lyon: IARC Scientific Publications, 1987, 1-406.
21. Preston DL, Lubin J, Pierce DA, McConney ME. EPICURE [software], release 2.0 edn. Seattle, WA: HiroSoft International, 1996.
22. McKnight B, Cook LS, Weiss NS. Logistic regression analysis for more than one characteristic of exposure. Am J Epidemiol 1999;149: 984-92.
23. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001;39:97-115.
24. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32.
25. Olsson H, Bladstrom A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 2003;102:565-70.
26. Schairer C, Hartge P, Hoover RN, Silverman DT. Racial differences in bladder cancer risk: a case-control study. Am J Epidemiol 1988;128: 1027-37.
27. D'Avanzo B, La Vecchia C, Negri E, Decarli A, Benichou J. Attributable risks for bladder cancer in Northern Italy. Ann Epidemiol 2005;5:427-31.
28. Mueller E, Latini J, Lux M, Stablein U, Brubaker L, Kreder K, Fitzgerald MP. Gender differences in 24-hour urinary diaries of asymptomatic North American adults. J Urol 2005;173:490-92.
29. Andrew A, Schned AR, Heaney JA, Karagas MR. Bladder cancer risk and personal hair dye use. Int J Cancer 2004;109:581-6.
30. Viel JF, Challier B. Bladder cancer among French farmers: does exposure to pesticides in vineyards play a part? Occup Environ Med 53: 587-92.
31. Hunter DJ, Manson JE, Colditz GA, Chasan-Taber L, Troy L, Stampfer MJ, Speizer FE, Willett WC. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56:373-8.
32. Bean JA, Leeper JD, Wallace RB, Sherman BM, Jagger H. Variations in the reporting of menstrual histories. Am J Epidemiol 1979;109:181-5.